Black Diamond Therapeutics (BDTX) Q3 2026 earnings review
Black Diamond wins FDA trial backing, but Phase 3 needs cash
Black Diamond Therapeutics, a clinical-stage cancer drug developer, won FDA backing for its Phase 3 lung cancer trial plan while its quarterly cash burn stayed steady. In updated Phase 2 data across 43 newly diagnosed lung cancer patients, silevertinib held median progression-free survival at 15 months and prevented any new brain tumors from forming. Chief executive Mark Velleca said the FDA meeting supports a path to both accelerated and full approval in a 400-patient global Phase 3 study starting in the second quarter of 2027.
| Phase 2 lung cancer progression-free survival | 15.0 months 0 new brain metastases at 15.9 months follow-up |
|---|---|
| Brain tumor response rate (CNS-ORR) | 86% 6 of 7 evaluable patients; accelerated approval endpoint |
| Ending cash and investments | $102.0M $8.3M used in operations in Q3 |
| Cash runway outlook | Unchanged into 2H 2028; max $12.8M/quarter burn by our math |
⚖️ Verdict: 🟢 Bullish
The story got better because the FDA agreed that brain tumor shrinkage can serve as an early approval endpoint, giving the drug a faster route to market in about a quarter of EGFR-mutant lung cancer patients. Two cautions stand out: the FDA requires safety data at the lower 150 mg daily dose before Phase 3 can open, and legal disclaimers reveal a proposed stock offering to pay for the Phase 3 readout rather than the partner funding assumed a year ago.
The question now is whether the lower 150 mg dose keeps the 200 mg dose's brain tumor activity and how much dilution it takes to fund the Phase 3 trial. Either a partner steps in and the 20-patient bridging cohort clears the FDA on time, or the company funds the 400-patient trial through equity sales alone. Cohort 4 safety results and financing terms ahead of the second-quarter 2027 trial launch will settle both points.
🐂 Bull Case
FDA Clears Path for Faster Lung Cancer Approval
Black Diamond Therapeutics develops silevertinib, an oral drug for non-small cell lung cancer (NSCLC) patients with uncommon epidermal growth factor receptor mutations (EGFR-NCM) that often spread to the brain. Chief executive Mark Velleca said the October 1 meeting with regulators "supports a clear path to potential accelerated and full approval" in newly diagnosed patients.
The company can seek early approval using brain tumor shrinkage inside a single Phase 3 trial rather than waiting years for overall survival results. The global study will enroll 400 patients across three groups, comparing a 150 mg daily dose against standard drugs osimertinib or afatinib.
- Main randomized group: 300 patients with untreated brain tumors, split evenly between silevertinib and standard care
- Additional single-arm groups: 80 patients without brain tumors and 20 patients with cancer in the spinal fluid
- Target start and readout: trial launch in the second quarter of 2027, with initial results in 2028
What to watch: completion of the 20-patient safety group at the 150 mg dose before the second quarter of 2027. Clearing that hurdle on time lets the drug developer open the Phase 3 trial on schedule.
Brain Tumor Control Holds Up Past Fifteen Months
Lung cancer with EGFR mutations frequently spreads to the brain, where older drugs struggle to cross the blood-brain barrier. Chief medical officer Sergey Yurasov said the drug's ability to "significantly delay CNS progression" drives its lasting benefit across all patients in the 43-patient Phase 2 trial.
With median follow-up now at 15.9 months, patients lived a median of 15.0 months before their cancer worsened, nearly matching the 15.2 months reported six months earlier. Clinical investigator Alex Spira noted that "not a single frontline patient treated with silevertinib has developed de novo brain metastases" during the study.
Among 24 patients who entered the trial without brain tumors, median progression-free survival reached 23.5 months, and 18 of the 43 total patients remain on treatment. What to watch: how many of the 18 remaining patients stay on therapy at the next clinical update in 2027, which will show whether durability holdspast two years.
Brain Cancer Trial Starts Randomized Dosing
Beyond lung cancer, Black Diamond is testing silevertinib in newly diagnosed glioblastoma (GBM), an aggressive brain cancer where roughly 30% of patients carry the EGFRvIII mutation. The biotech group originally planned to start the randomized portion of this Phase 2 study in the first half of 2026.
After finishing a six-patient safety test combining the 150 mg daily dose with standard chemotherapy temozolomide with no dose-limiting side effects, the trial dosed its first randomized patient in the fourth quarter of 2026. What to watch: interim progression-free survival results in the first half of 2028, which will test whether blocking the mutation slows brain tumor growth.
🐻 Bear Case
Phase 3 Costs Will Force a Stock Sale or Partner
Black Diamond states that its $102.0 million in cash and investments will fund operations into the second half of 2028. By our math, that eight-quarter window allows at most $12.8 million of quarterly cash burn, barely above the $8.3 million used in the third quarter before Phase 3 costs begin.
Running a 400-patient global Phase 3 lung cancer trial alongside a randomized Phase 2 brain cancer study will push clinical spending much higher. A year ago, the company's runway notes assumed a partner would pay for the Phase 3 lung cancer trial, yet no partner was announced with the Phase 3 plan.
Instead, the release's legal disclaimers mention "the completion of the proposed Offering and the expected use of proceeds therefrom, including the sufficiency of such proceeds to fund the Phase 3 program through the CNS-ORR readout". That language contradicts the impression that existing cash covers the new trial plan. What to watch: terms of a stock offering or licensing deal before Phase 3 starts in the second quarter of 2027, which will set the dilution for existing shareholders.
FDA Requires New Dose Data Before Phase 3 Starts
All 43 patients in the main Phase 2 lung cancer results started at a 200 mg daily dose of silevertinib, where prior disclosures showed 77% of patients needed a dose reduction and 84% had treatment interrupted. For the Phase 3 trial, Black Diamond chose a lower 150 mg daily dose to improve tolerability.
While regulators accepted the reason for the lower dose, the FDA requires safety data from enough patients in Cohort 4 — a 20-patient group testing 150 mg that began dosing in the third quarter — before the Phase 3 study can open. What to watch: Cohort 4 safety and response updates in the first half of 2027, because unexpected side effects or weaker brain tumor shrinkage at 150 mg would delay the Phase 3 launch.
Overhead Costs Jumped While Research Spending Fell
For a clinical-stage drug developer with no quarterly revenue, every dollar spent on corporate overhead leaves less cash for clinical trials. In the third quarter, total operating expenses rose 10.4% from a year ago to $12.1 million even though research and development (R&D) spending declined.
- General and administrative (G&A) overhead: $5.1 million, up 45.4% from $3.5 million a year ago
- Research and development (R&D) clinical spend: $7.0 million, down 6.2% from $7.4 million a year ago
- Overhead share of total operating expenses: 42.5% by our math, up from 32.3% in the prior-year quarter
The company attributed the overhead jump to an "increase in IP-related costs and higher non-income tax expense". What to watch: general and administrative spending in the fourth quarter, because recurring overhead above $5 million a quarter will shorten the cash runway once Phase 3 enrollment begins.
👓 Other Themes
Brain Response Rate Rests on Seven Evaluable Patients
Black Diamond highlights an 86% brain tumor response rate (CNS-ORR) as the centerpiece for accelerated approval. While 16 frontline lung cancer patients entered the Phase 2 trial with untreated brain metastases, only 7 had measurable brain lesions evaluable under the RANO-BM imaging standard (so 6 of 7 responded). The Phase 3 trial will test that rate across 300 randomized patients against standard drugs.
💲 Other KPIs
Cash reserves fell by $8.5 million from $110.5 million last quarter and are down from $128.7 million at the end of 2025. Net cash used in operations was $8.3 million, up 5.1% from $7.9 million a year ago and roughly in line with the $8.0 million burned in the second quarter.
The third-quarter net loss widened to $10.0 million, or $0.17 per share, compared with $8.5 million, or $0.15 per share, a year earlier. The loss stayed unchanged from $0.17 per share in the second quarter as higher legal and tax overhead offset lower Phase 2 trial expenses and lower interest income.
Weighted average diluted shares rose 0.9% from 56.9 million a year ago and 0.2% from 57.4 million in the second quarter. Stockholders' equity stood at $88.1 million at quarter-end, down 21.5% from $112.2 million at the end of 2025 due to ongoing operating losses.
🔮 Guidance
Unchanged. Black Diamond still expects its $102.0 million cash balance to fund anticipated operating and capital expenses into the second half of 2028. By our math, stretching $102.0 million across the eight quarters to the third quarter of 2028 caps average cash burn at $12.8 million per quarter, compared with $8.3 million used this quarter.
New. Following the October 1 FDA meeting, the company plans to open its 400-patient global Phase 3 lung cancer trial in the second quarter of 2027 and report preliminary data in 2028. Opening the trial requires submitting safety data from the ongoing 20-patient Cohort 4 at the 150 mg daily dose to the FDA first.
Unchanged. After dosing the first patient in the randomized Phase 2 brain cancer study in the fourth quarter of 2026, management narrowed the target for interim progression-free survival data from 2028 to the first half of 2028.
❓ Key Questions
How much capital will the Phase 3 trial require?
The forward-looking statements disclose a proposed stock offering to fund the Phase 3 trial through the brain response readout, while prior notes assumed a partner would pay for Phase 3. Investors need the total trial budget and whether partnering talks are still active.
How many Cohort 4 patients must finish safety follow-up?
The FDA requires safety data from a sufficient number of patients at the 150 mg daily dose in Cohort 4 before Phase 3 can open in the second quarter of 2027. Management has not stated how many of the 20 patients are enrolled or how long the FDA requires them to be followed.
What drove the 45% jump in overhead expenses?
General and administrative expenses rose by $1.6 million from a year ago to $5.1 million on intellectual property and non-income tax costs. Knowing how much of that increase is a one-off bill versus higher ongoing overhead matters for the cash burn rate.
When could the Servier partnership pay a milestone?
Black Diamond licensed its BDTX-4933 drug to Servier in 2025 for $70 million upfront and up to $710 million in milestones, which are excluded from the cash runway plan. Any near-term clinical milestone from Servier would reduce how much stock the company needs to sell.